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ABSTRACT: The concept of using precipitation inhibitors (PIs)
to sustain supersaturation is well established for amorphous
formulations but less in the case of lipid-based formulations (LBF).
This study applied a systematic in silico−in vitro−in vivo approach
to assess the merits of incorporating PIs in supersaturated LBFs
(sLBF) using the model drug venetoclax. sLBFs containing
hydroxypropyl methylcellulose (HPMC), hydroxypropyl methyl-
cellulose acetate succinate (HPMCAS), polyvinylpyrrolidone
(PVP), PVP-co-vinyl acetate (PVP/VA), Pluronic F108, and
Eudragit EPO were assessed in silico calculating a drug−excipient
mixing enthalpy, in vitro using a PI solvent shift test, and finally, bioavailability was assessed in vivo in landrace pigs. The estimation
of pure interaction enthalpies of the drug and the excipient was deemed useful in determining the most promising PIs for venetoclax.
The sLBF alone (i.e., no PI present) displayed a high initial drug concentration in the aqueous phase during in vitro screening. sLBF
with Pluronic F108 displayed the highest venetoclax concentration in the aqueous phase and sLBF with Eudragit EPO the lowest. In
vivo, the sLBF alone showed the highest bioavailability of 26.3 ± 14.2%. Interestingly, a trend toward a decreasing bioavailability was
observed for sLBF containing PIs, with PVP/VA being significantly lower compared to sLBF alone. In conclusion, the ability of a
sLBF to generate supersaturated concentrations of venetoclax in vitro was translated into increased absorption in vivo. While in silico
and in vitro PI screening suggested benefits in terms of prolonged supersaturation, the addition of a PI did not increase in vivo
bioavailability. The findings of this study are of particular relevance to pre-clinical drug development, where the high in vivo exposure
of venetoclax was achieved using a sLBF approach, and despite the perceived risk of drug precipitation from a sLBF, including a PI
may not be merited in all cases.
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super-SNEDDS, supersaturation, super-SMEDDS, supersaturating drug delivery systems
■ INTRODUCTION
Favorable solubility in gastrointestinal fluids and intestinal
permeability is a prerequisite for the high oral bioavailability of
any drug. However, drug discovery approaches such as high
throughput screenings, modifications during lead optimization,
as well as the noticeable therapeutic target shift toward
intracellular targets deliver more drugs, displaying low aqueous
solubility and beyond rule-of-five properties.1−3 These drug
candidates have sub-optimal biopharmaceutical properties,
which typically create a need for bioenabling formulation
approaches. The design of such formulations includes
strategies to generate and maintain high concentrations or
supersaturation in intraluminal fluids. Prominent examples of
such supersaturating formulations are amorphous solid
dispersions and the use of lipid-based formulations (LBF).4,5
In particular, for drugs with a low aqueous solubility, a high
lipophilicity and/or bioavailability that is increased by the co-
ingestion of fatty meals, LBFs can offer particular formulation
advantages.4−6 The most convenient and conventional LBFs
are lipid solutions, where the drug is dissolved in the lipid
vehicle and hence most widely applicable for drugs that show
high lipid solubility. Alternatively, for drugs which display low
solubility in lipid vehicles, strategies to increase dose loading in
the lipid vehicles may be required such as lipid suspensions,7−9
supersaturated LBFs (sLBF),10−13 lipophilic salts,14−16 or
lipid−hybrid systems.17−19
sLBFs can be beneficial in delivering drug candidates of this
type and interest in their application has increased over the
past years. The most common method to generate drug
supersaturation in lipids is by heating excess drugs in the lipids,
followed by cooling,12 whereupon the amount of dissolved
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drug in the lipid excipients may exceed the thermodynamic
solubility (at lower temperatures) and the LBF becomes
supersaturated. A supersaturated formulation should have at
least kinetic stability for practical handling, and sLBFs have
successfully been applied to improve the oral bioavailability of
a number of poorly water-soluble drugs such as cinnarizine,
simvastatin, and halofantrine.10,11,20−22 A sLBF formulation
approach offers a number of advantages, particularly in the
early stages of development. These advantages include the ease
of preparation, suitability for the ease of dosing in pre-clinical
models, and the ability to prepare prototype formulations on a
small scale while keeping the development costs low at times
where the attrition rate is usually high. Thomas et al.
developed a sLBF of simvastatin at 150% of the saturation
solubility and assessed bioavailability in dogs.10 The oral
bioavailability of the sLBF was 1.8-fold higher when compared
to the same dose of a LBF solution at 75% of the saturation
solubility.10 Recently, our group has reported that a sLBF of
venetoclax (containing venetoclax at 350% of the apparent
saturation solubility) increased oral bioavailability by 2.1-fold
when compared to a control LBF (i.e. lipid suspension) and
3.8-fold when compared to the crude drug powder.13
Additionally, the venetoclax study demonstrated during the
in vitro lipolysis testing of the sLBF that the drug concentration
of venetoclax in the aqueous digest phase was in the range of
the reported amorphous solubility in the fasted state simulated
intestinal fluid (FaSSIF).13 With such elevated aqueous phase
concentrations achieved by a sLBF, the risk of precipitation is
deemed high, and hence, it was hypothesized that the
incorporation of a precipitation inhibitor (PI) may be
beneficial.
While the incorporation of PIs in a supersaturated drug
delivery system has been widely explored for solid solutions, to
the best of our knowledge, no study has been reported to date
on the incorporation of PIs in sLBFs testing in vivo. A limited
number of studies have explored the use of PIs to reduce the
risk of drug precipitation upon the dispersion and digestion of
classical LBFs.23−26 The principle underpinning theory of
including PIs in (s)LBFs/solid solutions is commonly
described by the “spring and parachute” effect.27 These drug
delivery systems generate high initial supersaturated concen-
trations upon dispersion/dissolution, the so-called “spring”. To
prolong precipitation from the generated supersaturated
system for as long as possible, PIs act as a “parachute” by
hindering nucleation and arresting precipitation.27,28 This
fundamental advantage of prolonged supersaturated drug
concentrations in the intraluminal environment is assumed to
be beneficial for absorption in vivo.27,29,30 For example, Gao
and co-workers demonstrated a 10-fold higher oral bioavail-
ability by incorporating hydroxypropyl methylcellulose
(HPMC) into a undersaturated LBF compared to a HPMC-
free LBF in rats.25 Such formulations were described as
“supersaturable” by Gao and colleagues, primarily referring to
the ability of many LBFs to generate supersaturated drug
concentrations on dispersion/digestion in intestinal fluids.
However, it is worth noting that supersaturable LBFs explored
by Gao et al.23−25 contain drugs below saturation solubility and
are distinct from sLBFs even though this nomenclature is not
consistently used throughout the literature. The LBFs explored
in the studies by Gao and co-workers23−25 contained 70−100%
(w/w) co-solvents and surfactants [i.e. type IV of the lipid
formulation classification system (LFCS)],31,32 which, in
general, present a greater risk of drug precipitation on
dispersion. Similarly, Suys et al. recently reported that the
utility of PIs to prolong supersaturation was more evident for a
type IV (50% co-solvent) and type IIIB (25% co-solvent and
25% surfactants) formulation, whereas for a type IIIA
formulation (no co-solvent, 35% surfactant), the PIs studied
had no impact on prolonging supersaturation during in vitro
digestion.26 Collectively, these studies demonstrate the merits
of incorporating PIs in a LBF, where there is a perceived high
risk of precipitation on dispersion/digestion due to, for
example, a rapid co-solvent depletion. The aim of the present
study was to address the need to study the utility of PIs in
sLBFs using the model compound venetoclax.
The choice of suitable PIs, however, can be complicated23 as
the inhibitory effect is reported to be drug specific and there
are gaps in our understanding on which PIs are suited for a
particular drug type.26,27 While various in vitro screening tests
have been reported, to date the PI selection is mostly empirical
and there is a lack of comprehensive studies compared across
all the various PI types.27 Attempts have been made to increase
the mechanistic understanding to aid with the selection of PIs
to streamline formulation development;27 however, it is often
not known how effective an in vitro tool is in estimating the
impact on in vivo absorption, especially for rather complex
bioenabling formulations. In addition, given the complexity of
polymer−drug interactions, there is also a need for more
computational tools to guide excipient selection.
Venetoclax is a highly lipophilic drug (log P of 5.5)33 with a
high molecular mass of 868.44 g/mol33 and a melting point of
139 °C (Table S1), representing a recently licensed drug with
properties in the beyond rule-of-five space. The drug is
classified as a BCS class IV based on low aqueous solubility
and permeability. The commercial formulation Venclyxto
displays a pronounced food-dependent oral bioavailability
with a 3.4-fold increase in oral bioavailability after a low-fat
meal and a 5-fold increase after a high-fat meal compared to
the fasted state.33
This study explored the merits of PIs on the oral
bioavailability of an oil-based sLBF of venetoclax. A range of
promising PIs have been identified based on the calculated
excess enthalpy of mixing (COSMOquick software), which
served to estimate the molecular excipient interaction in the
more complex aqueous dispersions. The ability of the selected
PIs to maintain the supersaturation of venetoclax in biorelevant
media was tested in vitro, and the impact of incorporating PIs
into the sLBF in comparison to the separate addition (pre-
dissolved) of the PIs in the simulated intestinal fluids was
evaluated. A subsequent in vivo study examined the impact of
the incorporated PIs in sLBFs on the oral bioavailability of
venetoclax in landrace pigs.
■ MATERIALS AND METHODS
Chemicals and Materials. Venetoclax was purchased from
Kemprotec Ltd. (UK) (batch # 1810004). Olive oil, highly
refined and low acidity, taurodeoxycholic acid (NaTDC), and
pancreatic lipase (8× USP) were ordered from Sigma-Aldrich
(Ireland). Lipoid E PC S was obtained from Lipoid GmbH
(Germany) and Eudragit EPO was obtained from Evonik
(Germany). Hydroxypropyl methylcellulose acetate succinate
(HPMCAS) [AQOAT (HPMCAS-MF)] was purchased from
ShinEtsu (Japan) and Pluronic F108, HPMC, and poly-
vinylpyrrolidone (PVP) were purchased from MilliporeSigma
(St. Louis, MO, USA). Kollidon VA 64 (PVP/VA) was kindly
donated by BASF (Germany). Capmul MCM and Captex
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1000 were kindly donated by Abitec Corporation (US). A
sample of Peceol was kindly donated by Gattefosse ́ (France)
and SIF powder Version 1 was kindly donated by
biorelevant.com (UK). Water was purified by a Milli-Q water
system. All other chemicals and solvents were of analytical or
high-performance liquid chromatography (HPLC) grade and
were purchased from Sigma-Aldrich (Ireland) and used as
received.
Apparent Solubility. Apparent solubility was determined
in olive oil, Captex 1000, Peceol, and Capmul MCM. In brief,
an excess of venetoclax was added to 2 mL of the excipients
and stirred at 200 rpm (25% power) (Mixdrive 15, 2MAG,
Germany) at 37 °C. Solid excipients were melted at 50 °C and
cooled to 37 °C prior to venetoclax addition. Samples were
taken after 24, 48, and 72 h and centrifuged at 21,380g and 37
°C for 15 min (Mikro 200 R, Andreas Hettich GmbH & Co.
KG, Germany). The supernatant was transferred to a new
sample tube and centrifuged again under identical conditions.
To solubilize the oily excipient, the supernatant was diluted in
acetonitrile/ethyl acetate (1:3 v/v). Followed by further 1:10
(v/v) dilution with acetonitrile/ethyl acetate (3:1 v/v). The
obtained samples were diluted appropriately with the mobile
phase before analysis by reverse-phase HPLC as described
below. All samples were run in triplicates.
Biorelevant Solubility. FaSSIF and fed state simulated
intestinal fluid (FeSSIF) was prepared according to the
instructions by biorelevant.com. FeSSIF was used directly,
whereas FaSSIF was left at room temperature for 2 h prior to
usage. Excess venetoclax was added to 2 mL of biorelevant
media and placed in a water bath shaker at 200 shakes/min
(GLS400, Grant Instruments, UK) and 37 °C. Samples were
taken after 3, 6, and 24 h and centrifuged at 21,380g and 37 °C
for 15 min (Mikro 200 R, Andreas Hettich GmbH & Co. KG,
Germany). The supernatant was transferred to a new sample
tube and centrifuged again under identical conditions.
Subsequently, the supernatant was diluted with the mobile
phase before analysis by HPLC.
The samples were analyzed using an Agilent 1200 series
HPLC system (Agilent Technology Inc., US) that comprised a
binary pump, degasser, autosampler, and variable wavelength
detector. Data were analyzed using the software EZChrom
Elite version 3.2. Venetoclax was separated from the sample
matrix with a Zorbax Eclipse Plus-C18 column (5 μm, 4.6 mm
× 150 mm) including a Zorbax Eclipse Plus-C18 guard column
(5 μm, 4.6 mm × 12.5 mm) at 40 °C. The mobile phase
consisted of (a) acetonitrile with 0.5% trifluoroacetic acid
(TFA) and (b) water with 0.5% TFA at a ratio of 53:47 (a/b
v/v) and was used at a flow rate of 1 mL/min. The injection
volume was 20 μL and the detection wavelength was set to 316
nm. The limit of detection was 20 ng/mL and the limit of
quantification (LOQ) was 65 ng/mL determined using the
standard error of the y-intercept according to the International
Council for Harmonization (ICH) Q2 guidelines.34
Formulations for In Vivo and In Vitro Studies. In the in
vivo study and in vitro PI screens, the supersaturated lipid
solution (sLBF) was prepared as previously reported with a
lower temperature to reduce the thermal impact on the drug
and excipient.13 In brief, 300 mg of venetoclax were added to 6
mL of Peceol (50 mg/mL) and dispersed at 600 rpm (Stuart
CD162 heat-stir, Cole-Parmer, UK) and sealed with parafilm.
A continuous nitrogen stream into the vial removed oxygen
throughout the preparation. After suspending the drug
particles, the obtained suspension was slowly heated to 55
°C (Stuart CD 162 heat-stir, Cole-Parmer, UK). The mixture
was kept at 55 °C for 10 min and cooled to 25 °C while
continuously stirring at 600 rpm. Subsequently, the mixture
was heated a second time under the same conditions as stated
above and cooled to room temperature to obtain the final
sLBF. The absence of crystals was confirmed using cross-
polarized light microscopy. For the in vivo study, sLBF was
administered in hard gelatin capsule size 00EL (Licaps,
Capsugel, Lonza Group Ltd.) with 1 mL/capsule.
For the preparations of the sLBF with PI, HPMC,
HPMCAS, Pluronic F108, Eudragit EPO, PVP, and PVP-co-
vinyl acetate (PVP/VA) were added to the sLBF at a drug/PI
ratio of 1:1 (w/w). At the given PI concentration (50 mg/mL),
Pluronic F108, Eudragit EPO, PVP, and PVP/VA were soluble
in Peceol at 37 °C, while HPMC and HPMCAS resulted in a
suspension. In the case of the soluble PIs, the Peceol-PI
solution was used to prepare the PI containing sLBF using the
method described above. In the case of HPMC and HPMCAS,
the sLBF was prepared with Peceol as described above, and
HPMC and HPMCAS were added as the powder and
dispersed ad hoc into the sLBF before in vitro and in vivo
experiments. The amount of PI in the lipid vehicle (50 mg/
mL) was based on a previous work by Gao et al.23,24
Viscosity of Venetoclax Containing sLBFs. The
viscosity of the venetoclax containing sLBF and sLBF with
PIs was measured using a rotational viscometer (Discovery
HR-1, TA Instruments, USA) with a 60.0 mm plate and a 2.0°
cone (Peltier plate titanium, solvent trap, TA Instruments,
USA). The data were analyzed using a Trios V5.1.0.46403 (TA
Instruments, USA). Viscosity measurements were performed at
37 °C by pre-heating the formulations to 37 °C in a heating
cabinet and by allowing for a temperature equilibration time of
180 s prior to commencing the viscosity measurements. The
utilized method constituted three steps. First, a shear versus
viscosity curve was obtained by increasing the shear rate
stepwise (10 measurement points) from 0.0 to 600 1/s over
300.0 s (30 s/measurement point). Second, the shear rate was
set to 0.0 1/s for 60 s. Finally, the shear rate was set to 300 1/s
for 60 s with a sampling interval of 6.0 s/measurement point.
Cross-Polarized Light Microscopy. The absence of the
crystalline material in the supersaturated solutions was
confirmed by means of cross-polarized light microscopy
using an Olympus BX51 with an Olympus SC100 camera
operated by Olympus Stream essentials 2.3.3 (Olympus, UK).
The light was polarized using the polarizer U-POT (Olympus,
UK) and analyzed with the analyzer U-ANT (Olympus, UK).
The absence of crystals was assumed, if no birefringence was
observed.
In Vitro Evaluation: Drug Solubilization during
Formulation Dispersion and Digestion. In vitro lipolysis
was performed using a pH-stat apparatus (Metrohm AG,
Herisau, Switzerland) comprising a Titrando 907 stirrer, 804
Ti-stand, a pH electrode (Metrohm AG, Herisau, Switzerland),
and two 800 Dosino dosing units coupled to a 20 mL
autoburette. The system was operated by the Tiamo 2.2
software. The in vitro protocol was used as previously
reported.35 In brief, the buffer contained 2 mM TRIS maleate,
150 mM NaCl, and 1.4 mM CaCl2·2H2O, adjusted to pH 6.5.
For the digestion experiments, the buffer was supplemented
with 3 mM NaTDC and 0.75 mM PC (digestion buffer) and
stirred for 12 h before further usage. The pancreatin extract
was prepared freshly by adding 5 mL of 5 °C digestion buffer
to 1 g of porcine pancreatic enzymes (8× USP), which was
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vortexed thoroughly. The mixture was centrifuged for 15 min
at 5 °C, 2800g (Rotina 380 R, Andreas Hettich GmbH & Co.
KG, Germany), and 4 mL of the supernatant was recovered
and stored at 2−8 °C before further usage. The pancreatic
extract had a pancreatic lipase activity of ∼10,000 TBU/mL
(to provide approximately 1000 TBU per mL of digest), where
1 TBU represents the amount of the enzyme that liberates 1
μmol of FA from tributyrin per min.36
For the in vitro lipolysis experiment, 1.075 g of the lipid
formulation was dispersed into 39 mL of digestion buffer for
10 min. Three 1 mL samples were taken at 2.5, 5, and 10 min
from the middle of the vessel. pH of the media was adjusted
and maintained at 6.5 using 0.2 M NaOH. To the remaining
36 mL (1.0 g lipid formulation) of the dispersion, 4 mL of the
pancreatin extract was added to initialize digestion. After 60
min, the released nonionized free fatty acids were determined
by a pH increase of the buffer to pH 9. The stirring speed
throughout dispersion and digestion was set at 450 rpm.
Samples of 1.0 mL were taken at 5, 10, 15, 30, 45, and 60
min during the digestion experiment from the middle of the
vessel. In each sample and after 60 min, the enzymes were
inhibited by the addition of 1 M 4-bromophenylboronic acid in
methanol (5 μL per mL sample). Additionally, to each 1 mL
sample during digestion a 100 μL sample was taken and added
to 900 μL of acetonitrile and mixed. This sample was used to
quantify the total drug recovery, which allowed the adjustment
of inhomogeneous samples. All samples were centrifuged at 37
°C and 21,000g for 30 min using a benchtop centrifuge of the
type Hettich Micro 200 R (Andreas Hettich GmbH & Co. KG,
Germany).
In Silico PI Screening: COSMO-RS Calculations. The
excess enthalpy of mixing between venetoclax and the
polymeric PI was calculated using COSMOquick software
(COSMOlogic, Germany, Version 1.6). This software is based
on the conductor-like screening model for real solvents37,38
that combined quantum chemical surface charge calculations
with statistical thermodynamics. The COSMOquick approach
in particular allows for a fast calculation of surface charge
densities based on molecular fragments of previously calculated
compounds.39 Venetoclax and the polymers were entered in
smiles notation. As the quantum chemical calculations cannot
capture the full complexity of the polymers, such macro-
molecules have to be approximated and this study used trimers
for this purpose as previously described by Price et al. for
supersaturating formulations.40 The drug/PI ratio was set at a
stoichiometric ratio of 1:1 to represent the formulations used
in vitro and in vivo and the temperature was set to 37 °C. In
line with previous applications of COSMOquick for co-former
screening in co-crystal selection,41 drug solubility estimations
in glycerides,42 and polymer screening for supersaturated
formulations,40 a more negative value of the calculated excess
enthalpy ranks the strength of molecular drug−excipient
interaction. This is just an approximation, as the presence of
an aqueous phase is not considered in the calculations nor the
complexity of any biorelevant medium. Therefore, the results
should be understood as a first in silico estimation of relative
excipient comparison. This has previously been referred to as a
higher or lower “COSMO-Rank”.40
In Vitro PI Testing. The in vitro PI testing for venetoclax
was done by means of a solvent shift. The effect of a fully
hydrated PI (dissolved in FaSSIF) was compared against the
PI in the formulation. Thus, the employed PIs HPMC,
HPMCAS, Eudragit EPO, PVP, PVP/VA, and Pluronic F108
were dissolved in either FaSSIF or either suspended or
dissolved in the sLBF. For the hydrated PI test, 5 mg of PI was
dissolved in 5 mL of FaSSIF [prepared according to
biorelevant.com) and 5 mg of venetoclax dissolved in either
DMSO (100 mg/mL) or Peceol (sLBF 50 mg/mL] was
added. For the evaluation of the PI in the lipid formulation,
100 μL of the sLBF (50 mg/mL venetoclax and 50 mg/mL PI)
was added to 5 mL of FaSSIF. The vials were sealed and placed
in a water bath shaker at 200 shakes/min and 37 °C (GLS400,
Grant Instruments, UK). After 2, 5, 10, 15, 30, 60, 120, and
180 min, 250 μL samples were taken. The samples were
filtered with a 0.2 μm syringe filter (Whatman Spartan 13/0.2)
and samples that contained lipids were additionally centrifuged
for 30 min at 21,380g and 37 °C (Mikro 200 R, Hettich
GmbH, Germany). The aqueous phase was collected, and one
part was diluted 1:10 (v/v) with acetonitrile (including 0.5%
(v/v) TFA). A pure (nondiluted) and a diluted sample were
analyzed by HPLC as described above.
Additionally, the solubility of venetoclax was determined in
FaSSIF with dissolved PI. Excess venetoclax was added to 5
mL of FaSSIF with 5 mg of PI. 250 μL of samples were taken
at 3, 6, and 24 h and filtered through a 0.2 μm syringe filter
(Whatman Spartan 13/0.2), diluted with acetonitrile (con-
taining 0.5% (v/v) TFA), and analyzed by HPLC as described
above. Apparent supersaturation ratios (SRapp) were calculated
for each formulation based on the obtained FaSSIF solubility
and the measured venetoclax concentration in the 5 min
sample of the in vitro PI testing according the following
formula
=SR measured venetoclax concentration at 5 min
venetoclax FaSSIF solubilityapp
Evaluation of the sLBF Dispersion: Zeta Potential and
Droplet Size Analysis. sLBFs containing venetoclax were
prepared and dispersed in FaSSIF (at 37 °C) as described
above (1:50 (v/v) dilution). Samples (250 μL) were taken
after 5 and 60 min and diluted 1:250 (v/v) with FaSSIF V1.
The diluted samples were analyzed for its micellar/droplet size
and zeta potential using a Malvern Nano-Zetasizer (Malvern
Panalytical Ltd., UK). For the dynamic light scattering analysis
of the micellar/droplet size, the samples (1 mL) were
measured using disposable ZEN0040 cuvettes and the
micelles/droplet size was recorded according to the intensity-
based size distribution. Measurements were done in triplicates
at 37 °C, using 3 measurements with 12 runs of 10 s each. The
measurement angle was 173°. The dispersant medium was
customized as FaSSIF buffer containing the buffer salts and
sodium chloride (according to the concentrations in FaSSIF
V1)43 with a refractive index of 1.332 and a viscosity of 0.7252
cP. The material absorption was set to 0.01 and the material
refractive index to 1.44. The zeta potential was measured using
a folded capillary cell (DTS1070). Measurements were
performed in triplicate, at 37 °C, using 3 measurements with
12 runs of 10 s each.
In Vivo Study. All the experiments were approved and
conducted with licenses issued by the Health Products
Regulatory Authority, Ireland (project license AE19130/
P058) as directed by the EU Statutory instruments of the
EU directive 2010/63/EU (Protection of Animals used for
Scientific Purposes). Local ethical approval was granted by
University College Cork Animal Experimentation Ethics
Committee (AEEC). In order to test all PIs, two bioavailability
studies had to be conducted. The first study was with 5 pigs
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and a 6-way cross-over and the second study with 3 pigs and a
4-way cross-over. Both studies were randomized and
conducted in male landrace pigs (15−17 kg) and each pig
received a single dose of 100 mg of venetoclax. Pigs were fed
approximately 175 g of the standard weanling pig pellet feed
twice daily. In the fasted study legs, the final feed of 175 g was
given 24 h prior to dosing. As part of the study design, any
remaining food was removed 16 h before dosing; however, no
food remained at this point in any of the groups. On day 1, an
indwelling intravenous catheter was inserted from the ear vein
into the jugular vein under general anesthesia, which was used
for repeated blood sampling throughout the study. In the first
study, on day 3, following an overnight fast of 16 h, the pigs
were administered either sLBF or sLBF with PI, respectively.
The tested PIs included HPMC, HPMCAS, PVP, PVP/VA,
and Pluronic F108. In the second study, on day 3, following an
overnight fast of 16 h, pigs were administered either a
reference capsule with venetoclax powder, a venetoclax Peceol
suspension, a sLBF, or a sLBF including Eudragit EPO,
respectively. The results of the venetoclax powder, Peceol
suspension, and sLBF have previously been reported13 and are
not further described in the current study. In both studies, all
formulations were administered with the aid of a dosing gun,
followed by 50 mL of water via a syringe. In order to control
the water intake with the dosage forms, the water availability
was restricted for 3 h postdosing. At all other times, water was
available ad libitum. To facilitate handling during the oral
administration, an intramuscular dose of ketamine (5 mg/kg)
and xylazine (1 mg/kg) was administered in both studies.
Blood samples were collected after 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8,
9, 10, 12, and 24 h in heparinized tubes. Upon collection,
blood samples were immediately centrifuged at 3000g, 4 °C for
5.5 min (Eppendorf 5702 R, Rotor A-4-38, Eppendorf Ltd.,
UK). The supernatant plasma was harvested and stored at −20
°C until further analysis. A 6-day washout period was
maintained between the study legs.
Bioanalysis. The plasma concentrations of venetoclax were
determined by reversed-phase HPLC. The Agilent 1260 series
HPLC system (Agilent Technology Inc., US) comprised a
binary pump, degasser, temperature controlled autosampler,
column oven, and diode array detector. The system was
operated, and the data analyzed with EZChrom Elite version
3.3.2. A Zorbax Eclipse Plus-C18 column (5 μm, 4.6 mm ×
150 mm) with a Zorbax Eclipse Plus-C18 guard column (5
μm, 4.6 mm × 12.5 mm) were used for the separation of
venetoclax. The mobile phase consisted of water and
acetonitrile with 0.5% (v/v) TFA at a ratio of 47:53 (v/v)
and was used at a flow rate of 1.0 mL/min. The sample and
column temperature were set at 5 and 40 °C, respectively, and
the detection wavelength was set to 250, 290, and 316 nm.
Venetoclax was extracted from the plasma samples by liquid−
liquid extraction as reported previously.13 In brief, venetoclax
was extracted from 500 μL of the plasma using acetonitrile and
ethyl acetate. Vemurafenib was used as the internal standard.
The extraction solvents were dried under a nitrogen stream at
60 °C, and the residues were reconstituted in 100 μL of the
mobile phase (excluding TFA), followed by centrifugation at
25 °C, 11,500g for 5 min (Mikro 200 R, Andreas Hettich
GmbH & Co. KG, Germany). The injection volume used for
HPLC analysis of the supernatant was 50 μL.
Data Analysis. Prior to statistical analysis, the Bartlett’s test
was used to check for equal variances. A one-way analysis of
variance (one-way ANOVA) was performed for the lipolysis
and in vitro PI test data as well as the area under the curve
(AUC) of the in vitro PI test using Tukey’s post-hoc test to
compare the different formulation performances. The
pharmacokinetic parameters were calculated using Microsoft
Excel by means of the trapezoidal rule. The plasma
concentration profiles were analyzed by noncompartmental
analysis. The statistical analysis for the in vivo parameters of the
formulations within the same cross-over study was performed
using a one-way ANOVA after using the Bartlett’s test to check
for equal variances. The pairwise comparison of the groups was
done using Tukey’s multiple comparison test. All statistical
analyses were carried out using Prism version 5 by GraphPad.
■ RESULTS
Apparent Solubility of Venetoclax in Lipid Excipients.
Solubility screening in the pure lipid excipient indicated that
venetoclax showed a higher apparent solubility in the long
chain than the medium chain-based excipients (Figure 1A).
Within the long chain and medium chain excipients, a higher
apparent solubility was observed for the monoglycerides
compared to the triglycerides. Subsequently, the biorelevant
solubility of venetoclax was determined (Figure 1B). Solubility
in FaSSIF was 6.8 ± 1.8 μg/mL translating to only 1.7% of a
100 mg dose venetoclax in 250 mL of the gastrointestinal fluid.
In the fed state, the solubility increased 3.9-fold to 6.7% of the
Figure 1. (A) Venetoclax solubility in lipid excipients at 37 °C (n = 3, mean ± SD), (B) venetoclax solubility in FaSSIF and FeSSIF at 37 °C (n =
3, mean ± SD).
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100 mg of venetoclax dose, which in general is in agreement
with the observation in increased bioavailability for venetoclax
reported from clinical studies.33
sLBF Achieves High Aqueous Drug Concentration
during In Vitro Dispersion and Digestion. Previous
studies by our group developed a venetoclax sLBF using a
preparation method at 70 °C.13 Process optimization in this
study focused on improving the thermally induced super-
saturation process by lowering the overall energy input while
maintaining the desired level of supersaturation. sLBFs were
prepared at a target dose load of 50 mg/mL by heating a LBF
suspension (50 mg/mL) to 55 °C. The (s)LBF was kept at 55
°C for 10 min to dissolve venetoclax before cooling the
solution to room temperature. In this study, the obtained sLBF
had a 11.9-fold (1193.7%) higher drug load compared to the
apparent saturation solubility. The venetoclax concentrations
in the aqueous phase during dispersion and digestion are
shown in Table 1 and Figure S1.
As the drug needs to be dissolved prior to absorption by the
body, the solubilized drug in the aqueous phase of the in vitro
lipolysis test is often used as a guide to formulation
performance in vivo. The sLBF displayed relatively high
concentrations in the aqueous phase throughout in vitro
lipolysis, with an average venetoclax concentration of 18.6 ±
1.3 μg/mL during dispersion and 73.8 ± 6.4 μg/mL after 60
min of digestion. Interestingly, the final concentration of the
digestion (60 min) was equivalent to 6.4 ± 0.5% of the
venetoclax dose used in the experiment and was 2.8-fold higher
when compared to the apparent solubility of venetoclax in
FeSSIF. Additionally, the measured concentration was higher
than the reported amorphous solubility in FeSSIF of 26.4−
54.6 μg/mL.44 Most of venetoclax was recovered in the lipid
phase with an average of 98.5 ± 2.8% of the venetoclax dose
during dispersion and 88.6 ± 0.2% after 60 min of digestion
(Figure S1). The lipid phase can act as a reservoir for the drug,
which gradually diffuses into the aqueous phase during the
transit through the gastrointestinal tract. Additionally, the lipid
phase is digested during the transit releasing venetoclax. In the
case of the sLBF, the lowest amount of venetoclax was
recovered in the solid phase. sLBF showed no precipitation
during dispersion and after 60 min of digestion only 6.2 ±
0.6% of the venetoclax dose was precipitated. These results are
in line with previous studies showing a superior performance
(a high-aqueous-phase concentration and a low-solid-phase
concentration) of the sLBF in vitro relative to a lipid-based
suspension and an aqueous suspension.13 The optimized
processing method, therefore, yielded a comparable formula-
tion performance.
COSMO-RS as a Preliminary In Silico Screening Tool
for PI Selection. To identify the most promising PIs, reduce
the extent of in vitro testing, and to evaluate the utility of this
computational tool in the formulation design of sLBFs, the
interactions between venetoclax and various PIs were evaluated
in silico. Based on the COSMO-RS theory37,45 that combines
quantum chemistry and statistical thermodynamics, COSMO-
quick software was utilized to predict binary PI−drug
interactions similarly to previous reports, where this screening
technique of PI selection was utilized for silica formulations.40
COSMOquick software predicts the interactions of two
molecules based on equilibrium thermodynamics and the
predicted chemical potential in liquids. The stronger the
interaction between venetoclax and the PI, the more negative
the calculated excess enthalpy of interaction. A simplified view
assigns to a PI that has a more negative excess enthalpy, a
higher “COMSO-Rank” with respect to its suitability as PI.
While this tool may be beneficial to reduce in vitro testing by
identifying the most promising PI−drug interactions as shown
for other formulation approaches,40 it must be acknowledged
that the in silico calculations did not consider the presence of
water nor other formulation excipients, potentially limiting the
applicability of this approach for the more complex bioenabling
formulation approach of LBFs. In the present study, the excess
enthalpy of mixing for a variety of PIs was calculated, and PIs
with varying negative enthalpy of mixing were selected. The
chosen PIs had the following “COSMO-Rank”: Eudragit EPO
> Pluronic > HPMCAS ≥ PVP ≥ PVP/VA > HPMC as shown
in Figure 2.
In Vitro Testing of PIs for Prolonging Supersatura-
tion. The selected PIs from the in silico screening were further
evaluated experimentally in vitro to assess the PI performance
(aqueous phase concentration) under simulated conditions
and with LBFs. The in vitro PI test was performed by means of
the solvent shift by dispersing the formulation in (i) FaSSIF or
Table 1. Venetoclax Concentration in the In Vitro Lipolysis
Experiment after 10 min of Dispersion and after 5 and 60
min of Digestiona
venetoclax concentration (μg/mL) in aqueous phase








sLBFb 18.7 ± 0.0 37.5 ± 3.2 73.8 ± 6.4
LBF suspensionc,d 1.0 ± 0.1 1.7 ± 0.3 2.9 ± 0.5
aqueous
suspensiond
3.0 ± 0.1 9.1 ± 0.2 9.4 ± 0.3
aVenetoclax was formulated as sLBF (50 mg/mL), Peceol suspension
(50 mg/mL), and aqueous suspension (50 mg/mL). All the
experiments were run with n = 3 and results are shown as mean ±
SD. bsLBF drug loading was 1194% of determined apparent solubility.
cLBF drug loading was 100% solubilized + 158% suspended of
determined apparent solubility. dData as previously reported.13
Figure 2. COSMOquick screen. Calculated excess enthalpy of
interaction between venetoclax and the PIs. The dark gray PIs were
selected for further in vitro and in vivo evaluation. The calculation was
based on a 1:1 ratio of drug to PI. PLA: polylactic acid, PGA:
polyglycolic acid, HPMCAS: hydroxypropyl methylcellulose acetate
succinate, PVP: polyvinylpyrrolidone, PVAc: polyvinyl acetate, PLGA:
polylactic-co-glycolic acid, PVP/VA: polyvinylpyrrolidone-co-vinyl
acetate, HPMC: hydroxypropyl methylcellulose, HEC: hydroxypropyl
cellulose, MC: methylcellulose, and PVA: polyvinyl alcohol.
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(ii) FaSSIF with pre-dissolved PI (FaSSIF-PI). In FaSSIF-PI
was dispersed (a) venetoclax dissolved in DMSO (100 mg/
mL) as positive control (DMSO control) and (b) sLBF (sLBF-
aqPI). In FaSSIF was dispersed (c) sLBF without PI (sLBF-
noPI) and (d) sLBF with incorporated PI (sLBF-PI). Polymers
that were soluble at the tested concentration of 50 mg/mL
were dissolved in sLBF (PVP, PVP/VA, Pluronic F108,
Eudragit EPO) and those that were not soluble in the sLBF
were therefore ad hoc suspended in the sLBF (HPMC,
HPMCAS). The concentration of PI in the sLBF was based on
previous reports by Gao et al.23,24 Additionally, the solubility of
venetoclax in FaSSIF-PI was measured. The apparent super-
saturation of the formulations was calculated using the
venetoclax concentration after 5 min of dispersion, relative to
the FaSSIF solubility. The apparent supersaturation ratio
indicates the apparent fold increase in the venetoclax
concentration above the FaSSIF solubility at the given time
point. The results of the PI testing are shown in Figure 3 and
Table 2.
In all cases, the venetoclax solubility in FaSSIF-PI was higher
compared to the solubility in FaSSIF with an increase in
solubility from 1.3-fold to 3.4-fold. In order of decreasing
solubility in FaSSIF-PI, the ranking was Eudragit EPO, HPMC,
Pluronic F108, PVP/VA, HPMCAS, and PVP. In general,
upon the dispersion of the DMSO solution in FaSSIF-PI
HPMC, Pluronic F108, PVP/VA, HPMCAS, and PVP,
venetoclax concentrations reached FaSSIF-PI solubility,
which was maintained throughout the experiment. In the
case of Eudragit EPO, a decrease below the FaSSIF-PI
solubility was observed.
In the case of the sLBF-noPI, a high initial concentration
was observed (14.5 ± 1.7 μg/mL), which was above the
FaSSIF solubility (5.2 ± 0.4 μg/mL). In addition, the initial
venetoclax concentrations of sLBF-noPI was above FaSSIF-PI
in the case of HPMC, PVP/VA, HPMCAS, PVP, and Pluronic
Figure 3. In vitro evaluation of the venetoclax concentration profile during the dispersion of sLBFs in FaSSIF (mean ± SD with n = 3). The dashed
line represents the apparent venetoclax solubility in FaSSIF with pre-dissolved PI (FaSSIF-PI) and the solid line represents FaSSIF solubility. The
dotted line (◊) represents the sLBF alone dispersed in FaSSIF (sLBF-noPI). Venetoclax dissolved in DMSO dispersed in FaSSIF-PI (DMSO
control) (●), sLBF dispersed in FaSSIF-PI (sLBF-aqPI) (▲), and sLBF with PI (sLBF-PI) dispersed in FaSSIF (Δ).
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F108, indicating that the investigated PI-free sLBF-noPI was
able to generate supersaturation, that is, a spring effect upon
dispersion. The observed initial spring effect venetoclax
concentrations of the sLBF-noPI were also similar to all the
initial aqueous phase concentrations of DMSO control, which
had the PIs pre-dissolved in the media. Relative to the FaSSIF
solubility, an apparent supersaturation ratio of 2.2 ± 0.5 after 5
min of dispersion was observed for the sLBF-noPI (Table 2).
The degree of supersaturation from the sLBF-noPI gradually
decreased to 1.3 ± 0.2 after 2 h, whereas at 3 h, the drug
concentration had dropped to FaSSIF solubility. However,
while the sLBF-noPI was not able to maintain supersaturated
concentrations throughout the experiment, the use of PIs in
the positive control maintained supersaturation for up to 3 h.
As the function of the PIs was intended as a “parachute” to
prolong supersaturation, the results indicated a beneficial
precipitation inhibitory effect of PIs on the formulation
performance.
Interestingly, the combination of PIs in sLBF (sLBF-PI)
yielded a higher spring concentration in the case of HPMCAS,
PVP, PVP/VA, and Pluronic F108 when compared to sLBF-
noPI and DMSO control. While the sLBF-PI with HPMC
showed an initial venetoclax concentration similar to sLBF-
noPI, sLBF-PI with Eudragit EPO resulted in a statistically
significant lower venetoclax concentration in the media when
compared to sLBF-noPI and DMSO control (p < 0.05). In
fact, the venetoclax concentration was below FaSSIF and
FaSSIF-PI solubility when Eudragit EPO and lipid were
present simultaneously. In the case of dispersing sLBF into
FaSSIF-PI (sLBF-aqPI), an increased initial venetoclax
concentration was only evident for Pluronic F108 when
compared to sLBF-noPI. All other PIs resulted in a similar or
decreased initial concentration. However, the increased
venetoclax concentration in the presence of Pluronic F108
might also be attributed to the additional solubilization effects
of Pluronic F108 as a non-ionic surfactant.
The impact of polymer-sLBF combinations on the ability to
solubilize venetoclax and prolong supersaturation across six
different PIs is summarized in Table 2 and Figure 3. In the case
of HPMC, HPMCAS, and Eudragit EPO, the sLBF-aqPI
resulted in a lower amount of solubilized venetoclax
throughout the experiment compared to sLBF-noPI. Similarly,
in comparison to DMSO controls, the sLBF-aqPI resulted in a
lower AUC in the case of Eudragit EPO, HPMC, HPMCAS,
and PVP/VA. As an example, the amount of the solubilized
venetoclax dose was 0.033 ± 0.002% for Eudragit EPO in the
case of sLBF-aqPI. In addition, sLBF-aqPI resulted in the case
of Eudragit EPO, HPMC, HPMCAS, PVP, and PVP/VA in a
similar or lower apparent supersaturation ratio compared to
sLBF-noPI and the respective DMSO controls. In the case of
Pluronic F108, the amount of venetoclax solubilized and the
apparent supersaturation ratio were increased compared to the
sLBF-noPI and DMSO control. This may be attributed to the
surfactant properties of Pluronic F108, which can lead to an
improved dispersibility of the sLBF and higher solubility of
venetoclax. Overall, the results of the sLBF-aqPI suggested that
a pre-dissolved PI in FaSSIF was less effective at prolonging
venetoclax supersaturation, indicating that concomitant admin-
istration (i.e., chase dosing) a PI with a sLBF would not
potentially offer benefits in terms of the sustained high
concentrations for absorption in vivo.
In the case of incorporating HPMC, HPMCAS, PVP, PVP/
VA, and Pluronic F108 within the sLBF a higher amount of
venetoclax was solubilized compared to sLBF-noPI. Further-
more, the sLBF-PIs resulted in a higher amount of solubilized
venetoclax in comparison to the sLBF-aqPI. In addition, higher
apparent supersaturation ratios (after 5 min of dispersion)
were observed for sLBF-PI relative to sLBF-noPI. In the case
of HPMC, HPMCAS, PVP, and PVP/VA, the apparent
supersaturation ratios were higher compared to the sLBF-aqPI,
indicating that these sLBF-PI combinations achieved a balance
between generating and maintaining supersaturated concen-
trations. However, Pluronic F108 and Eudragit EPO did not
follow this trend. Pluronic F108 showed a higher super-
saturation ratio and % solubilized venetoclax for the sLBF with
pre-dissolved Pluronic F108 (sLBF-aqPI), compared to the
incorporation into the sLBF (sLBF-PI). Such high venetoclax
concentrations and supersaturation ratios in the presence of
Pluronic F108 may be attributed to the surfactant nature of the
polymer, which can increase the solubilization capacity of the
test media, especially when pre-dissolved. In the case of
Eudragit EPO, a significantly decreased amount of solubilized
venetoclax and supersaturation ratios <1 in all cases of lipid
excipient-PI combinations were observed.
Based on the amount of venetoclax solubilized in the in vitro
PI test, the general performance ranking was Pluronic F108 >
Table 2. AUC of the In Vitro PI Testing for sLBF Dispersed in FaSSIF-PI (sLBF-aqPI), sLBF with PI Incorporated in the
Formulation (sLBF-PI) and Dispersed in FaSSIF (FaSSIF-PI), Venetoclax Dissolved in DMSO and Dispersed in FaSSIF-PI
(DMSO control), and sLBF Alone Dispersed in FaSSIF (sLBF-noPI); % Solubilized Venetoclax and Apparent Supersaturation
Ratio for sLBF-aqPI and sLBF-PI as Well as Apparent FaSSIF-PI Solubility (Mean ± SD, n = 3)







[μg/mL] sLBF-aqPI sLBF-PI sLBF-aqPI sLBF-PI
Eudragit EPO 1.9 ± 0.3 0.1 ± 0.004 0.1± 0.02 17.6 ± 0.8 0.03 ± 0.002 0.1 ± 0.01 <LOQ 0.3 ± 0.03
HPMC 2.6 ± 0.5 0.7 ± 0.1 2.9± 0.3 11.5 ± 2.4 0.4 ± 0.04 1.6 ± 0.2 0.9 ± 0.2 2.3 ± 0.2
HPMCAS 3.0 ± 0.3 0.9± 0.03 9.1 ± 0.4 7.9 ± 1.6 0.5 ± 0.02 5.1 ± 0.2 0.8 ± 0.1 8.3 ± 0.3
PVP 1.8 ± 0.3 1.5 ± 0.2 13.5 ± 0.1 6.7 ± 0.2 0.9 ± 0.1 7.5 ± 0.04 1.7 ± 0.2 2.9 ± 0.4
PVP/VA 2.8 ± 0.2 1.6 ± 0.2 8.8 ± 0.3 8.1 ± 1.4 0.9 ± 0.1 4.9 ± 0.2 3.0 ± 1.6 4.3 ± 0.3
Pluronic F108 2.0 ± 0.4 50.4 ± 2.4 17.5 ± 0.6 8.9 ± 0.2 28.1 ± 1.3 9.8 ± 0.3 7.9 ± 0.2 4.6 ± 0.2
sLBF-noPI 1.8 ± 0.3 1.0 ± 0.2 2.2 ± 0.5
a% solubilized was calculated by dividing the AUC of the concentration versus time profiles by the maximum AUC, that is, representing 100%
solubilized, over the same period of time. bApparent supersaturation ratio (SRapp) of venetoclax after 5 min dispersion (SRapp = determined
venetoclax concentration/venetoclax FaSSIF solubility).
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PVP > HPMCAS ≥ PVP/VA > HPMC > Eudragit EPO in the
case of sLBF-PI and Pluronic F108 > PVP/VA ≥ PVP ≥
HPMCAS ≥ HPMC > Eudragit EPO in the case of sLBF-aqPI.
While this performance ranking was not in line with the in silico
calculated COSMO-Rank, it should be acknowledged that
Eudragit EPO was not able to generate supersaturated
venetoclax concentrations in the presence of the lipid
excipient. Therefore, this particular PI may not be suitable to
enhance the sLBF performance. Subsequently, the relationship
between the in vitro determined solubilized venetoclax and the
in silico calculated COSMO-Rank was reassessed without
Eudragit EPO. The results for sLBF-PI and sLBF-aqPI are
summarized in Figure 4. It was evident that there is a trend
that a higher COSMO-Rank, that is, higher interaction
between venetoclax and the PIs resulted in a higher
supersaturation ratio in the aqueous phase of the in vitro test
in the case of sLBF-PI. From the in silico screen and in vitro
experiments, a relationship between COSMO-Rank and
venetoclax solubilization and supersaturation was less evident
for sLBF-aqPI (no relationship was observed after 180 min).
The results of both approaches (in silico and in vitro) indicated
that for this lipid system an overly strong interaction between
the drug and the PI may be less favorable, and in the case of
Eudragit EPO, it resulted in the depletion of aqueous
venetoclax concentrations.
Impact of PIs on In Vivo Bioavailability of Venetoclax
from sLBFs. The aim of the in vivo study was to explore
whether the in vitro observations would translate to in vivo
using sLBF-PI across six different PIs. Venetoclax formulations
(50 mg/mL) were prepared as a supersaturated Peceol
solution alone (sLBF-noPI) or in combination with HPMC,
HPMCAS, PVP, PVP/VA, Pluronic F108, and Eudragit EPO
at a ratio of 1:1, respectively. PVP, PVP/VA, Pluronic F108,
and Eudragit EPO were readily soluble in the sLBF, whereas
HPMC and HPMCAS were not soluble in the sLBF and were
therefore mixed in the sLBF prior to oral administration. An
oral dose of 100 mg of venetoclax was used. Absolute
bioavailability was determined with reference to the intra-
venous data that has been previously reported for landrace
pigs.46 The absolute bioavailability as a function of each
formulation is shown in Figure 5 and the associated
pharmacokinetic parameters presented in Table 3. Individual
plasma profiles for all tested formulations are shown in Figures
S2 and S3 in the Supporting Information. While it was only
feasible to conduct a full six by six way cross-over study in this
experiment facility, a seventh study leg using Eudragit EPO
was performed in a separate group of three pigs. In this case
only mean comparisons were possible, whereas for all other
groups formulation differences within each pig were
performed.
Figure 4. Relationship between excess enthalpy of mixing (calculated in silico using COSMOquick) and in vitro determined apparent
supersaturation ratio after 5 and 180 min, respectively, for sLBF-PI added to FaSSIF (FaSSIF-PI) and sLBF added to FaSSIF-PI (sLBF-aqPI).
Eudragit EPO was excluded from the data set due to the inability to generate supersaturation. Data are presented as mean ± SD, n = 3.
Figure 5. Absolute bioavailability (Fabs) in landrace pigs for 100 mg
venetoclax as a 6-way crossover with sLBF-noPI, sLBF-HPMC, sLBF-
HPMCAS, sLBF-PVP, sLBF-PVP/VA, and sLBF-Pluronic F108 and
an additional study including sLBF-Eudragit EPO. All data are
presented as mean ± SD, where n = 5 (except sLBF-Eudragit EPO,
where n = 3).
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The sLBF-noPI showed the highest mean bioavailability
(26.3 ± 14.2%) compared to all other tested lipid
formulations. An increased bioavailability was not observed
by the incorporation of PIs but rather a trend toward a
decreased oral bioavailability, albeit only the sLBF-PVP/VA
formulation displayed statistically significant lower bioavail-
ability relative to the sLBF-noPI (p < 0.05). The rank order of
the oral bioavailability was sLBF-noPI ≥ sLBF-HPMCAS ≥
sLBF-HPMC ≥ sLBF-Pluronic F108 ≥ aLBF-PVP ≥ sLBF-
Eudragit EPO ≥ sLBF-PVP/VA. The observed bioavailability
for sLBF-noPI is in agreement with previously reported
venetoclax bioavailability in fasted pigs (17.3 ± 5.5%). The
time to reach the maximum plasma concentrations (tmax), the
mean residence time (MRT), and mean absorption time
(MAT) tended to increase with lower oral bioavailability. In
addition, a delayed appearance of venetoclax in the plasma was
observed in the case of sLBF-PI. However, both observations
were not statistically significant different. Overall, the results
showed that the use of PIs did not enhance the sLBF
formulation performance in vivo.
sLBF Viscosity and Droplet Size Impact on In Vitro
and In Vivo Performances. The in vitro and in vivo tested
sLBF containing venetoclax and the evaluated PIs (sLBF-PI)
were further assessed for their viscosity. In addition, upon
dispersion in the FaSSIF, droplet size as an indicator for the
available surface area and zeta potential as an indicator for the
stability of the dispersion were investigated to probe the
impact of these formulation parameters on the observed in vivo
and in vitro behavior. The in vitro dispersion was performed as
described in the in vitro testing for PIs by dispersing sLBF-PI in
FaSSIF (1:50 dilution). PVP, PVP/VA, Pluronic F108, and
Eudragit EPO were dissolved in sLBF, and HPMC and
HPMCAS were ad hoc suspended in the sLBF due to a low
solubility in the formulation. The results of the viscosity
measurements are shown in Table 4, and the results of the
droplet size and zeta potential measurements are shown in
Table 5.
At low (30 1/s) and medium (150 1/s) shear rates, the
lowest viscosity was observed for the sLBF-noPI, while the
highest viscosity was observed for sLBF-Pluronic F108. At a
high shear (300 1/s), the lowest viscosity was observed for
sLBF-HPMC (75 ± 3 mPa s) and the highest for sLBF-PVP
(493 ± 1 mPa s). Thus, while a shear thinning effect was
especially pronounced for sLBF-Pluronic F108 and sLBF-
HPMC, in the case of Eudragit EPO, HPMCAS, PVP, PVP/
VA, and sLBF-noPI, no significant viscosity decrease was
observed with the increasing shear rate.
The droplet size formed on the dispersion in biorelevant
media varied between formulations and was influenced by the
dispersion time. After 5 min of dispersion, the highest droplet
size was observed in the case of sLBF-PVP, while after 60 min
of dispersion, the highest droplet size was observed for sLBF-
HPMCAS. In the case of sLBF-noPI, an initial droplet size of
320 ± 49 nm was observed, which decreased to 197 ± 58 nm
after 60 min of dispersion. In the case of the highly viscous
formulations containing Pluronic F108, PVP, and PVP/VA, a
high initial (after 5 min) droplet size was reached. However,
the droplet size decreased on sampling after 60 min dispersion.
In contrast, initially the low viscous sLBF-HPMC and sLBF-
HPMCAS dispersed well with droplet sizes of approximately
170 nm, but a significant increase in the droplet size was
observed after 60 min of dispersion. This indicated that
viscosity influenced dispersibility of the formulations among
other factors. (e.g., surfactant-like properties of Pluronic F108).
In the case of sLBF-EPO, the droplet size appeared to be
consistent over the 60 min; however, sampling for sLBF-EPO
is not homogeneous due to large agglomerates, as illustrated in
Figure S4.
Table 3. Pharmacokinetic Parameters for Venetoclax after Oral administration of 100 mg/pig to Male Landrace Pigsa
pharmacokinetic parameters
sLBF-noPI sLBF-HPMC sLBF-HPMCAS sLBF-PVP sLBF-PVP/VA
sLBF-Pluronic
F108 sLBF-Eudragit EPOc
cmax [μg/mL] 1.38 ± 0.84 0.92 ± 0.24 0.83 ± 0.20 0.81 ± 0.19 0.48 ± 0.67 0.80 ± 0.20 0.51 ± 0.28
tmax [h] (range) 6 (2−10) 6 (6−8) 8 (7−10) 8 (6−8) 9 (8−10) 9 (6−10) 10 (7−10)
AUC 0 hinf.
[μg·h/mL]
11.40 ± 6.15 7.39 ± 1.40 7.69 ± 2.53 6.90 ± 1.83 4.73 ± 1.08 7.19 ± 1.50 5.23 ± 1.60



























b 100 76.62 ± 32.34 78.86 ± 37.81 72.22 ± 30.56 52.95 ± 29.23 80.24 ± 42.16 68.87 ± 21.01d
Fabs [%] 26.28 ± 14.20 17.25 ± 2.63 17.57 ± 5.80 15.84 ± 4.18 10.76 ± 2.44 16.39 ± 3.47 11.95 ± 3.64
venetoclax appearance
in plasma [h]
0.5 (0.5−2.0) 1 (0.5−1.5) 2 (1.5−2.0) 1.5 (0.5−2.0) 2 (2.0−3.0) 1.5 (0.5−3.0) 1.5 (0.5−3.0)
aVenetoclax was administered in a six-way crossover as a supersaturated Peceol solution (sLBF-noPI) and as sLBF with HPMC (sLBF-HPMC),
HPMCAS (sLBF-HPMCAS), PVP (sLBF-PVP), PVP/VA (sLBF-PVP/VA), and Pluronic F108 (sLBF-Pluronic F108) and in a two-way crossover
including Eudragit EPO (sLBF-Eudragit EPO). Tmax, MAT, MRT, and the appearance of venetoclax in the plasma are given as median (range),
while all other parameters as mean ± SD (n = 5, except sLBF-Eudragit EPO, where n = 3). bRelative to sLBF. csLBF-Eudragit EPO originated from
a second in vivo study. sLBF for the second in vivo study has previously been published.13 dRelative to a previously published sLBF.13
Table 4. Viscosity Measurements of Venetoclax Containing
sLBF-PI Formulations at Shear Rates of 30, 150, and 300 1/
s at 37 °C (Mean ± SD, n = 3)
viscosity [mPa s]
30 1/s 150 1/s 300 1/s
sLBF-Eudragit EPO 326 ± 17 325 ± 16 324 ± 13
sLBF-HPMC 231± 64 130 ± 11 75 ± 3
sLBF-HPMCAS 139 ± 6 127 ± 6 122 ± 6
sLBF-PVP 498 ± 12 494 ± 12 493 ± 1
sLBF-PVP/VA 377 ± 9 372 ± 9 361 ± 6
sLBF-Pluronic F108 2439 ± 402 709 ± 34 312 ± 11
sLBF-noPI 93 ± 15 91 ± 15 89 ± 10
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Upon the dispersion of the sLBF-noPI and sLBF-PI, a
negative zeta potential was obtained in all cases. The zeta
potential was below −30 mV in the case of sLBF-noPI and
between −30 and −20 mV in the case of sLBF with PVP/VA,
HPMC, HPMCAS and Eudragit EPO. A higher zeta potential
was observed in the case of sLBF-PVP (−14 ± 2 mV) and
sLBF-Pluronic F108 (−1 ± 0.2 mV). Thus, on average no
trends were observed on the zeta potential between
formulations.
■ DISCUSSION
Bioenabling formulations that enhance the extent of oral drug
absorption are increasingly required to meet the challenge of
poor water-soluble properties of drugs emerging from
discovery pipelines. Drug candidates which fail to meet
Lipinski’s rule-of-five criteria are a common target for such
bioenabling formulation strategies2 due to poor biopharma-
ceutical properties, resulting from low aqueous solubility and/
or poor permeability. Ideally, a formulation design that rapidly
generates elevated drug concentrations in the gastrointestinal
fluids, that is, that generates the so-called “spring effect” to
increase the concentration above the saturation solubility in
gastrointestinal fluids and therein promote absorption.27,29,30
In recent years, LBF approaches have been mechanistically
described as “supersaturable” drug delivery systems, on the
basis of generating supersaturation following dispersion/
digestion in the intraluminal environment. Indeed, it is widely
recognized that dispersion/digestion can present a key risk to
prolonged supersaturation, where there is a lower solubilization
capacity of the post digestive milieu. In particular, LBFs that
contain high % of co-solvents (such as LFCS type IV systems)
are considered to be at the greatest risk of drug precipitation in
the gastrointestinal tract. In order to prolong the onset of
precipitation, PIs have been used.
The present study, therefore, aimed to explore the utility of
PIs to enhance performance for sLBFs, where the API
concentration exceeds thermodynamic solubility in the
formulation. Our group and others have previously shown
that sLBFs enhance oral bioavailability of poorly water-soluble
drugs; albeit, there is a perceived risk of drug precipitation due
to the systems being considered merely kinetically stable. To
address this, in the current study, the utility of several PIs to
enhance formulation performance of a sLBF of venetoclax has
been evaluated in vitro and in vivo. We further calculated the
excess enthalpy of mixing of the drug and various polymers to
approximate the interaction between venetoclax and the PIs in
a more complex aqueous environment. This approach
facilitated a rationalization of in vitro testing, which was
based on a solvent shift to assess the precipitation inhibitory
effect.
The in vitro lipolysis confirmed the ability of sLBF to
generate supersaturated aqueous phase concentrations of
venetoclax during dispersion and digestion, which exceeded
the experimentally determined apparent solubility in FaSSIF
(Figure 1) and the reported values for the experimentally
determined amorphous solubility in FaSSIF (20.7 ± 0.5 μg/
mL, pH 5.3; 33.7 ± 13.5 μg/mL, pH 6.9) and FeSSIF (26.4 ±
0.2 μg/mL, pH 5.3; 54.6 ± 2.0 μg/mL, pH 6.9).44 Such
elevated concentrations were not observed for an aqueous and
lipid-based suspension and therefore confirm the ability of
sLBF to generate supersaturated drug concentrations on
dispersion/digestion in intestinal fluids. Additionally, as a
class III glass former13 and due to the high molecular weight,
venetoclax tends to crystallize more slowly. Moreover,
venetoclax has been reported to undergo liquid−liquid-phase
separation at concentrations above the amorphous solubility,
and it was assumed that supersaturation is maintained for a
duration that is physiologically promising (24 h).44 While in
the case of the sLBF, the physical state of the drug in such a
separated drug-rich phase is unknown, it can potentially serve
as a reservoir of the absorbable drug.44 The co-existence of a
drug-rich phase and an aqueous phase at amorphous solubility
(which were not separated) may explain the amount of
venetoclax measured above the amorphous solubility in this
test setup.
The in vitro PI screening method revealed that the
incorporation of the PI into the sLBF resulted in a higher
venetoclax concentration in the aqueous phase compared to
the addition of sLBF to the media containing pre-dissolved PI.
Interestingly, the sLBF formulation demonstrated an initial
supersaturated venetoclax concentration, which was main-
tained for up to 2 h even in the absence of a PI (i.e. sLBF-
noPI). These findings are in line with the observations during
in vitro lipolysis and confirm the ability of sLBF approaches to
generate supersaturation, that is, to act as a spring. The
incorporation into the sLBF (sLBF-PI) of the PIs: PVP/VA,
HPMCAS, PVP, Pluronic F108, and HPMC, proved beneficial
for venetoclax, resulting in prolonged supersaturation in vitro
(apparent supersaturation ratio >2.4 for all polymers after 180
min of dispersion). However, the incorporation of Eudragit
EPO resulted in a decreased venetoclax concentration in the
aqueous phase to below FaSSIF solubility (0.08-fold reduction
relative to FaSSIF solubility). It was also noticeable that the
sLBF-Eudragit EPO was poorly dispersible in FaSSIF, forming
a two-phase system with drug-rich agglomerates dispersed in
buffer (Figure S4). In contrast, all the sLBF-noPI and sLBFs
containing PIs dispersed consistently in FaSSIF to form a
Table 5. Droplet Size and Zeta Potential of Venetoclax Containing sLBF-PI Dispersions in FaSSIF after 5 and 60 min of
Dispersiona
droplet size [nm] PDI zeta potential [mV]
5 min 60 min 5 min 60 min 5 min 60 min
sLBF-Eudragit EPO 107.2 ± 12.8 103.8 ± 3.6 0.53 (0.41−0.71) 0.77 (0.62−0.80) −23.7 ± 1.2 −21.7 ± 1.0
sLBF-HPMC 175.7 ± 33.7 467.8 ± 132.6 0.30 (0.23−0.37) 0.35 (0.30−0.62) −23.5 ± 3.0 −20.1 ± 1.9
sLBF-HPMCAS 167.8 ± 30.3 515.3 ± 150.3 0.44 (0.31−0.81) 0.47 (0.35−0.64) −24.6 ± 1.3 −16.8 ± 1.2
sLBF-PVP 403.1 ± 156.8 200.3 ± 9.5 0.32 (0.25−0.61) 0.25 (0.16−0.32) −14.1 ± 1.5 −16.2 ± 0.8
sLBF-PVP/VA 392.0 ± 35.0 256.1 ± 59.6 0.39 (0.30−0.45) 0.30 (0.21−0.32) −24.3 ± 0.7 −21.2 ± 2.7
sLBF-Pluronic F108 325.0 ± 44.1 163.6 ± 19.8 0.35 (0.27−0.42) 0.31 (0.26−0.45) −1.1 ± 0.2 −0.9 ± 0.2
sLBF-noPI 320.1 ± 48.6 197.0 ± 56.7 0.35 (0.31−0.42) 0.26 (0.21−0.30) −31.2 ± 1.2 −33.9 ± 0.9
aPDI is given as median (range), while all other parameters as mean ± SD (n = 3).
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homogenous dispersion on mixing. One possible explanation
for the significantly lower venetoclax concentrations observed
for the sLBF-Eudragit EPO system may reflect the poor
dispersion in FaSSIF. This observation suggested that
venetoclax may have remained within the lipid-rich agglom-
erates and was not released from the formulation into the
aqueous phase. Additionally, Eudragit EPO (in the unionized
form, expected in neutral and alkaline conditions, pKa ∼ 647)
and venetoclax are relatively lipophilic and interact strongly
with each other, as indicated by the calculated negative excess
enthalpy of the interaction with the in silico tool, which may
have further promoted the drug retention in the lipid phase.
Another aspect is that the unionized Eudragit EPO was not
expected to swell in aqueous medium and such a swelling of a
more hydrophilic polymer is likely to contribute to the
performance of a PI. This complexity in aqueous medium was
not captured by the simple mixing enthalpy calculations of
binary drug-polymer systems.
The in vivo study demonstrated that the highest mean oral
bioavailability was obtained with the sLBF-noPI. However, a
high variability for cmax, tmax, and AUC was observed. The
sLBF-PI formulations showed a trend toward a decreased oral
bioavailability, when compared to sLBF-noPI. The overall
bioavailability of 26.3 ± 14.2% for sLBF-noPI is in line with
previous reports of venetoclax bioavailability in large animal
models.13,48 However, the results of the present study were
unexpected because previously published studies exploring the
inclusion of PIs with LBF resulted in an increased
bioavailability.23−25 However, in the previously reported
studies, LFCS-type IIIB/IV LBF systems were used, which
contained high amounts of co-solvents and exhibited a high
risk of precipitation due to the dilution effect upon
dispersion.26 Therefore, this confirmed that the ability of an
oil-only sLBF to generate supersaturated concentrations of
venetoclax in vitro was translated to increased absorption in
vivo and that the duration of the supersaturation for the sLBF
was sufficient to obviate the inclusion of a PI. This observation
that a PI was not required may be specific for venetoclax, given
that the drug as a class III glass former has a low tendency to
crystallize.44 Hence, for other drugs such as poor glass formers
as well as sLBF containing higher proportions of co-solvents
further studies are required to assess whether sLBF approaches
with PIs are needed to maximize absorption and mitigate a
perceived risk of precipitation in vivo.
The median MAT for the sLBF-PI formulations was higher
among all PI containing formulations relative to sLBF-noPI
(Table 3). Overall, given the variability in the absorption rate
of venetoclax in each group, no statistically significant
differences were observed. However, it would appear that the
inclusion of a PI may present a risk of a delayed absorption
that may reflect a delay of drug release from the formulation
(as evident by the delayed onset of venetoclax appearance in
the plasma for sLBF-PI, Table 3). An explanation for this
observation might be a combined effect of the extent of the
drug−polymer interaction and a reduced polymer swelling.
The incorporation of the PI into the sLBF may have reduced
polymer swelling (which normally happened in the aqueous
media) and caused trapping of the drug. In addition, the
interaction between the PIs and the drug reduces the diffusion
of both PI and the drug, and hence, the partitioning of
venetoclax and PIs from the sLBF to the aqueous phase.
The partitioning may be further reduced due to an increased
viscosity of the sLBF-PI formulations as observed in this study
(Table 4), which further decreases the diffusion of the drug
from the inner part of the lipid droplets toward the bulk. The
viscosity data revealed that at low and moderate shear, which
would be expected in vivo in pigs,49 the viscosity for all tested
sLBF-PI was higher compared to LBF-noPI. In addition, a
higher viscosity might also lead to a decreased dispersibility
(e.g., as observed in vitro in the case of Eudragit EPO, Figure
S4, or PVP and Pluronic F108, Figure 3), and subsequently
digestibility and drug release. While a higher viscosity of sLBF-
PVP, sLBF-PVP/VA, and sLBF-Pluronic F108 and a lower
viscosity of sLBF-HPMC and sLBF-HPMCAS resulted in an
initial high- and low-lipid droplet size upon dispersion,
respectively, the results of the lipid droplet size analysis are
not apparent in the case of sLBF-noPI and sLBF-Eudragit
EPO. In addition, the observed change of the droplet size
during a prolonged period of dispersion in this study indicated
that besides the initial dispersibility and viscosity other factors
such as the complex interactions between PI, lipid, drug, and
the dispersion media might have an impact on the dispersion
and drug release of the sLBF-PI. However, further studies are
needed to explore the effect of these parameters on sLBF
performance in vivo.
From the in vivo data, it appears that the solubility of the
polymer in the sLBF may have impacted the bioavailability. In
the cases of PIs being soluble in the sLBF, that is, Pluronic
F108, PVP, PVP/VA, and Eudragit EPO dissolved completely
in the sLBF, a lower bioavailability was observed when
compared to the PIs that showed a lower solubility in the
sLBF, that is, HPMC and HPMCAS formed suspensions in the
sLBF. One explanation for this observation may be that a PI
that is soluble in the lipid vehicle can, in combination with a
high drug affinity of the PI, lead to a drug retention in the
vehicle instead of showing a more favorable PI functionality of
reducing precipitation once the sLBF has dispersed in the
intraluminal fluids. On the other hand, a more hydrophilic
polymer that is suspended in the sLBF may lead to polymer
swelling upon aqueous dispersion to allow for drug release and
the intended PI functionality. Further studies exploring
polymer solubility in sLBF and its effect on drug release may
therefore be merited to fully predict the impact of PIs on in
vivo performance.
Overall, a relationship between the in silico calculated excess
enthalpy of mixing and the in vitro determined supersaturation
ratios and amounts of venetoclax solubilized was established in
the case of PIs that generated supersaturated concentrations.
This study showed that with increasing “COSMO-Rank” (i.e.,
lower excess enthalpy of mixing), higher apparent super-
saturation ratios and higher amounts of solubilized venetoclax
were obtained. Because Eudragit EPO resulted in under-
saturated aqueous solutions (venetoclax concentration below
FaSSIF saturation solubility) due to a lower release from the
formulation, the PI was not considered in the analysis of the
relationship between in silico and in vitro. However, the result
of Eudragit EPO showed a simple consideration of the high
negative excess enthalpy for a more lipophilic polymer in sLBF
and should be interpreted with care regarding PI performance.
The deviation of the in vivo results from the in silico
calculations by COSMOquick software may reflect an
oversimplification of the calculated parameters. The calcu-
lations considered the interactions between the drug and the
PI, but the interaction between the drug or the PI with
formulation excipients, water, or the components of gastro-
intestinal fluids such as bile salts and phospholipids were not
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taken into account. While this might have not been crucial for
an in vitro dispersion experiment, the digestion of the lipid
excipients in vivo further increased the complexity of the
gastrointestinal fluids, by releasing fatty acids and other
digestion products in the gastrointestinal environment. It is,
hence, unclear whether a drastic simplification to solely the
drug and PI by the selected COSMOquick approach is
applicable for LBFs to define PIs. Nevertheless, the current in
silico approach may be useful for type IV LBFs/sLBFs that
contain less digestible excipients, that is, co-solvents, and may
be a quick screening tool to reduce the initial PI choice to a
reasonable number, which subsequently can be tested in vitro
and in vivo. Furthermore, the complementing in vitro and in
silico techniques used in the present study may be helpful in
understanding the formulation behavior of sLBFs in vivo.
A lack of PI impact on the increasing bioavailability may also
reflect that the in vitro model was poorly predictive of the in
vivo situation. The reasons for the in vitro test not being
predictive of a reduced overall drug absorption in the presence
of PIs can be manifold such as (a) more complex intestinal
conditions in vivo,50 (b) a lack of the absorptive sink in vitro,51
or (c) a venetoclax specific effect. The employed in vitro test
exhibited a high drug and lipid load as well as higher
hydrodynamics compared to in vivo. Furthermore, especially,
the high venetoclax concentration in the presence of Pluronic
F108 may have been influenced by the surfactant properties of
the polymer leading to an overpredictive result in vitro. In
addition, a solvent shift may meet the industry need for a fast
screening tool; however, in the case of LBFs, it is not
physiologically relevant. A combined dispersion/digestion
setup26 or a dispersion/digestion setup with an absorptive
sink52−54 may provide more mechanistic, albeit lower
throughput, results. A further limitation of the study may
have been the incorporation of the PI into the sLBF. While this
decision was guided by in vitro data, in light of the in vivo
results, it is unclear whether separating the PI and sLBF may
have conferred advantages in vivo.
■ CONCLUSIONS
The formulation approach of using PIs to prolong super-
saturation is well recognized for amorphous formulations but
less well explored for sLBFs. The present study was applied in
silico, in vitro, and in vivo models to extend the concept of PIs
in an oil-only sLBF. An in silico tool was used for an initial PI
selection and aided in explaining the low free venetoclax
concentration in vitro in the case of the sLBF with Eudragit
EPO. It was found that the strong predicted interaction
between the drug and the polymer may have led to an overall
reduction in the venetoclax release from the formulation. In
addition, the in vitro PI screening tool showed that the
incorporation of the PI into the sLBF yielded higher free drug
concentrations compared to the separate addition of the PI.
While the in vitro screening showed prolonged supersaturated
venetoclax concentrations in the presence of PIs in five out of
six cases, an in vivo trend toward a lower overall bioavailability
was observed for PI containing formulations, indicating that
incorporating a PI into the sLBF was not necessary. The oral
bioavailability of venetoclax was the highest for the PI-free
sLBF-noPI, which suggests that the reduced oral absorption
due to precipitation from an oil-only sLBF was low.
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